Efficacy of Mohs micrographic surgery versus conventional surgery for basal cell carcinoma and squamous cell carcinoma: a systematic review and meta-analysis

• Grant number: 22/14884-7
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: February 01, 2023
• End date: December 31, 2023
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Luciana Patrícia Fernandes Abbade
• Grantee: Natalia Miranda Luna
• Host Institution: Faculdade de Medicina (FMB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil

Abstract

Introduction: Basal cell carcinoma (BCC) accounts for 70-80% of malignant skin neoplasms, followed by squamous cell carcinoma (SCC), which is responsible for the largest number of metastatic disease associated with skin cancer. Micrographic surgery (MS) has a satisfactory cost-effectiveness ratio in the treatment of these high-risk skin cancers, with minimal recurrence rates and high preservation of healthy tissue. Objective: To compare the efficacy and safety of MS using the Mohs technique versus conventional surgery (CS) for high-risk BCC and SCC, considering recurrence rate, metastases and specific mortality rate and complications. Methods: Systematic review and meta-analysis, with search for articles in PUBMED, LILACS, EMBASE, SCOPUS, WEB OF SCIENCE, CINHAL and COCHRANE. Randomized clinical trials (RCT) and non-randomized controlled studies involving patients with BCC or SCC and indication for MS by Mohs technique will be included. The control group will be the treatment through the CS. Study selection and data extraction will be performed by two peer reviewers, as will the risk of bias assessment using the Joanna Briggs Institute tool. Combined estimates will be evaluated by random effects model and heterogeneity will be evaluated by I2 statistic or chi-square test (chi2 or c2). Analyzes will be performed using Stata Software version 17.0. Expected results: this review will summarize the data regarding the rate of recurrence, metastases, mortality and complications of the main treatments recommended for high-risk skin tumors, ie CM in relation to CC. In this way, it may contribute to the choice of the best therapy for non-melanoma skin malignancies.